This study is a phase 2, randomised, placebo-controlled, multicentre study to investigate the
safety and efficacy of Deferiprone in participants with Prodromal Alzheimer's Disease (pAD)
and Mild Alzheimer's Disease (mAD). In this phase 2 study, the investigators aim to determine
whether Deferiprone (15 mg/kg BID orally) slows cognitive decline in Alzheimer's patients. As
secondary outcomes, safety and iron levels in the brain will be evaluated.